Clinical Trials Logo
  1. Home
  2. Takayasu Arteritis
  3. NCT05102448

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Takayasu Arteritis Clinical Trial

Official title:
Comparison of the Efficacy and Safety of Tofacitinib and Methotrexate Based on Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Trial

Clinical Trial Summary

The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis

Clinical Trial Description

Takayasu's arteritis (TAK), a chronic large vessel vasculitis, involves the aorta and its main branches. Glucocorticoids and immunosuppressants such as methotrexate, cyclophosphamide are common agents for TAK treatment. However, their effects for remission induction and relapse prevention are not satisfied. More effective agents for TAK treatment remain to be investigated. Tofacitinib (TOF) is a Jak inhibitor, which has been proved to be effective in multiple autoimmune diseases such as rheumatoid arthritis. Our preliminary real-world study also demonstrated a promising treatment effect of TOF in patients with TAK. But its efficacy and safety needs further verification. The present randomized controlled trial aimes to compare efficacy between methotrexate and tofacitinib in TAK treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05102448
Study type Interventional
Source Shanghai Zhongshan Hospital
Contact Lindi Jiang, Ph.D., M.D.
Phone 021-64041990
Email zsh-rheum@hotmail.com
Status Recruiting
Phase Phase 4
Start date November 1, 2021
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04564001 - Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis Phase 2
Terminated NCT04882072 - A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Phase 3
Completed NCT03750929 - Aerobic Capacity and Strength Exercise in Takayasu's Arteritis N/A
Recruiting NCT04137614 - Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis N/A
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT03893136 - The Registry Study of Takayasu Arteritis in East China
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT03096275 - Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis Phase 3
Recruiting NCT04299971 - Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Phase 4
Recruiting NCT04300686 - A Pilot Study in Severe Patients With Takayasu Arteritis. Phase 4
Recruiting NCT03192878 - Infliximab Biosimilar in Takayasu's Arteritis N/A
Active, not recruiting NCT04071691 - PET Imaging of Giant Cell and Takayasu Arteritis
Recruiting NCT05904301 - Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Completed NCT02101333 - Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Phase 3
Not yet recruiting NCT03550781 - Anti-inflammatory Treatment for Inactive Takayasu Arteritis Phase 2/Phase 3
Active, not recruiting NCT05168475 - Biologics in Refractory Vasculitis Phase 2
Completed NCT03956394 - Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging N/A
Recruiting NCT05151848 - Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Phase 4
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT02925351 - Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases Early Phase 1